UPDATED

The trial data published in the NEJM last week focused exclusively on adults 18 to 64, even though nearly 60% of the Phase 3 clinical trial participants were 65 or older — suggesting Pfizer intends to heavily market its mRNA flu vaccine to older adults. The trial data omitted from the NEJM study, but published on ClinicalTrials.gov, revealed a high rate of serious adverse events among elderly trial participants.

The data, published only on ClinicalTrials.gov, showed that elderly participants who received the mRNA flu shot faced a greater risk of serious adverse events, including kidney failure and acute respiratory failure.

https://childrenshealthdefense.org/defender/pfizer-omitted-trial-data-showing-higher-mortality-kidney-failure-seniors-mrna-flu-shot/?

AND

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

https://clinicaltrials.gov/study/NCT05540522

AND

Pfizer mRNA Influenza Vaccine ‘Failed’ In Clinical Trial Among Seniors: FDA Commissioner

“The trial showed zero benefit…”

https://www.zerohedge.com/medical/pfizer-mrna-influenza-vaccine-failed-clinical-trial-among-seniors-fda-commissioner